Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen in China
Amgen started to establish an affiliate in China since 2012, with the goal of making more of its innovative medicines available to patients in China. Over the years, Amgen has brought to the local market some of its advanced products through strategic partnerships, and established its China headquarter in Shanghai after opening a representative office in Beijing. Besides, Amgen is conducting multiple clinical studies in China, planning to introduce more innovative medicines to Chinese patients to help them combat severe illnesses such as oncology and cardiovascular diseases.
Taking active part in Chinese government’s scheme of accelerating the development of innovative drugs and therapies, Amgen is at the forefront of improving the efficiency and speed of new drug introduction. With a strong foothold in China, Amgen proactively explores cooperation with leading domestic pharmaceutical companies, demonstrating its commitment to providing Chinese patients with innovative medicines and therapies. Driven by the commitment to act in the public interest and improve drug accessibility, we fully leverage our long-standing development and biologics manufacturing expertise to develop biosimilars. In September 2017, Amgen China announced a strategic collaboration with Simcere Pharmaceutical Group to co-develop and commercialize four biosimilars in the areas of inflammation and oncology. Leveraging Simcere’s capabilities in developing innovative pharmaceuticals and branded generic drugs, this partnership aims to accelerate the development and launch of high quality biosimilars in China.
Upholding its commitment to scientific excellence, Amgen places great importance on research and development and exploits its advantages in this area to the full, while continuously expanding external collaborations in China. In 2013, Amgen partnered with ShanghaiTech University to establish its Asia R&D Center on the campus. Inaugurated in 2014, Amgen Asia R&D Center was relocated to a new permanent lab in Zhangjiang Hi-Tech Park in March 2017, adjacent to top research institutes and prestigious universities. Amgen will continue to deepen its partnership with local research facilities, and advance the research and development of innovative medicines supported by top-quality clinical development and translational science research capabilities to better serve Chinese patients.